UK's NICE issues final guidance on Daiichi Sankyo's Lixiana for stroke and systemic embolism
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Lixiana (edoxaban) from Daiichi Sankyo (TYO: 4568) to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation.
Lixiana received European marketing authorization in June 2015 for two indications: prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation, and treatment of deep vein thrombosis (DVT) and pulmonary embolism, and prevention of recurrent DVT and pulmonary embolism in adults.
Lixiana is a novel oral anticoagulant, one of a class of drugs that is used as an alternative to warfarin, which has been widely used for over 50 years but requires frequent monitoring to ensure the drug is working properly and is also associated with many food and drug interactions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze